Reprogramming within Hours Following Nuclear Transfer into Mouse but not Human Zygotes by Egli, Dieter et al.
 
Reprogramming within Hours Following Nuclear Transfer into
Mouse but not Human Zygotes
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Egli, Dieter, Alice E. Chen, Genevieve Saphier, Justin Ichida,
Claire Fitzgerald, Kathryn J. Go, Nicole Acevedo, et al. 2011.
Reprogramming within hours following nuclear transfer into
mouse but not human zygotes. Nature Communications 2: 488.
Published Version doi:10.1038/ncomms1503
Accessed February 19, 2015 1:08:13 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11315437
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAReprogramming within hours following nuclear transfer into
mouse but not human zygotes
Dieter Egli1,2,4,7, Alice E. Chen1,2, Genevieve Saphier1, Justin Ichida1, Claire Fitzgerald1,
Kathryn J. Go5, Nicole Acevedo5, Jay Patel5, Manfred Baetscher1, William G. Kearns6,
Robin Goland7, Rudolph L. Leibel7, Douglas A. Melton1,2,3, and Kevin Eggan1,2,3,8
1Department of Stem Cell and Regenerative Biology, Harvard University, 7 Divinity Ave,
Cambridge MA 02138
2Harvard Stem Cell Institute, Harvard University, New York, NY
3Howard Hughes Medical Institute, Harvard University, New York, NY
4 The New York Stem Cell Foundation Laboratory, New York, NY
5Reproductive Science Center, One Forbes Road, Lexington MA
6The Center for Preimplantation Genetics, Rockville, MD
7Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, New
York, NY
Abstract
Fertilized mouse zygotes can reprogram somatic cells to a pluripotent state. Human zygotes might
therefore be useful for producing patient-derived pluripotent stem cells. However, logistical, legal
and social considerations have limited the availability of human eggs for research. Here we show
that a significant number of normal fertilized eggs (zygotes) can be obtained for reprogramming
studies. Using these zygotes, we found that when the zygotic genome was replaced with that of a
somatic cell, development progressed normally throughout the cleavage stages, but then arrested
before the morula stage. This arrest was associated with a failure to activate transcription in the
transferred somatic genome. In contrast to human zygotes, mouse zygotes reprogrammed the
somatic cell genome to a pluripotent state within hours after transfer. Our results suggest that there
is a previously unappreciated barrier to successful human nuclear transfer, and that future studies
should focus on the requirements for genome activation.
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tIntroduction
The generation of animals by nuclear transfer1,2 and the derivation of human embryonic
stem cells3, suggested that these two approaches might be combined to generate patient-
specific embryonic stem lines. Because they would carry the patient's genotype, such stem
cells might be useful for the production of autologous transplants4,5 and for disease
modeling6. Studies in mice have demonstrated the potential value of these combined
approaches for treating severe combined immune deficiency and Parkinson's disease7,8.
Although it is now possible to produce pluripotent stem cell lines with patient genotypes
using defined reprogramming factors9,10, the equivalency of these cells to embryonic stem
cells has been questioned. Several groups have found differences in gene expression, DNA
methylation and differentiation propensity between iPS cells and ES cells11-15. Further, it
has been suggested that induced pluripotent stem cells are not reprogrammed to the same
extent that is observed in embryonic stem cells following nuclear transfer16. Therefore, it
remains important to pursue human nuclear transfer as an alternative approach for producing
stem cell lines.
However, despite several attempts at human nuclear transfer17-24, these efforts have
uniformly failed to produce stem cell lines. Instead, most studies reported developmental
arrest during the cleavage stages. Consistent with this, the only stem cell line purportedly
derived by human nuclear transfer25 has subsequently been shown to originate from
parthenogenesis rather than reprogramming of a somatic nucleus26.
We have recently generated mouse embryonic stem cells by nuclear transfer into mitotic
zygotes27, demonstrating that these cell-types might also be a useful supplement to oocytes
for human studies. Here we report programs for the acquisition of human preimplantation
embryos, resulting in the donation of a significant number of human zygotes. When we
performed nuclear transfer, development proceeded through the cleavage stages but arrested
around the time of compaction. Our investigation into the causes of this blockade revealed
that this developmental arrest is the result of a failure to undergo transcriptional activation of
the transferred somatic chromosomes. Thus, there is a barrier to reprogramming following
human nuclear transfer that must be overcome before patient-specific embryonic stem cell
lines can be derived.
Results
Donation of human zygotes
Because we have had difficulty in accessing sufficient numbers of unfertilized oocytes to
proceed with nuclear transfer studies24, we considered the possibility that human zygotes
could serve as a source of recipient cytoplasm for nuclear transfer. We therefore initiated a
program for recruitment of couples willing to donate their frozen zygotes for research. These
protocols were approved by the participating academic institutions’ committees on the use
of human subjects in research, stem cell research oversight committees and by the Western
Institutional Review Board, an Associate of the Accreditation of Human Research
Protection Programs. Between January 2007 and May 2010, 4061 IVF embryos were
donated by couples undergoing assisted reproduction. Though the majority of these were
cryopreserved at either the cleavage- or blastocyst-stages, 461 (11.3%) were frozen at the 1
cell-stage and therefore useful for nuclear transfer (Fig.1a). These human zygotes were in
excess of clinical need, but otherwise normal.
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For successful reprogramming, we had previously cultured interphase mouse zygotes until
they entered the first mitosis and only then carried out nuclear transfer27. To investigate the
reprogramming potential of human zygotes, we thawed 386 frozen human zygotes of which
307 (80%) were viable. Of these, 259 (84.4%) contained one maternal and one paternal
pronucleus, as is typical for the first interphase in a normal, diploid, zygote (Fig.1a). These
zygotes entered mitosis within 0-12 hours after thaw (Fig.1b), assembled a bipolar spindle
(Fig.1c), and of 28 control zygotes, 9 (32%) developed to the blastocyst stage
(Supplementary Table S1). To better understand why not all zygotes developed to the
blastocyst stage, and to exclude zygotes with low developmental potential from use in
nuclear transfer experiments, we analyzed the first mitosis in more detail. Another group has
previously reported that progression through the first mitosis can accurately predict
developmental potential28. Closer inspection of zygotes entering into mitosis revealed
asynchrony of nuclear envelope breakdown. 34/82 zygotes (41%) did not simultaneously
break down their two pronuclei, but instead did so with a delay of 30min to up to 12 hours
(Fig. 1d,e). When 1PN (pronuclear) zygotes were stained for phosphorylation of Histone
H3, a mitosis-specific modification of chromatin imposed by AuroraB kinase, we observed
extensive phosphorylation on chromosomes of the pronucleus that had broken down, but not
on chromatin of the pronucleus that had retained a nuclear envelope (3 of 3 zygotes) (Fig.
1f). In addition, we observed a variety of other idiosyncrasies in human zygotes entering
into mitosis. These included failure to condense the chromosomes (Supplementary Figure
S1a), a failure to completely dissolve nucleoli (Supplementary Figure S1b) and a failure to
assemble a mitotic spindle (Supplementary Figure S1c). Zygotes exhibiting these
abnormalities either arrested as single cells or eventually underwent fragmentation, and were
excluded from use in nuclear transfer.
The underlying cause of abnormalities we observed in frozen zygotes was not entirely clear.
There was substantial variation in the age of frozen zygotes donated to us, with the oldest
having been cryopreserved for as many as 20 years (Supplementary Figure S2). We do not
favor the idea that these problems are a direct side effect of the freeze-thaw process, as 3/3
human zygotes frozen in mitosis were able to assemble a spindle within 30min of thawing
(Supplementary Figure S3) and because mouse zygotes frozen and thawed entered mitosis
normally and could be used for nuclear transfer (Supplementary Table S2).
In the context of early nuclear transfer experiments, which controlled for micromanipulation
of the human zygote, we found that the mitotic spindle could not properly direct cytokinesis
if it's position or orientation was disturbed (Supplementary Figure S4-S6). We therefore
devised a nuclear transfer strategy for human zygotes that was analogous to nuclear transfer
into oocytes, thus overcoming this difficulty (Fig. 2a).
In this novel nuclear transfer strategy, 69 human interphase zygotes were placed into
medium containing the microtubule-depolymerizing drug nocodazole (Fig.2b). In all cases,
these human zygotes proceeded into the first mitosis (Fig.2c), but then as intended, arrested
due to inhibition of spindle assembly. This arrest in mitosis induced by nocodazole was
stable but reversible and nontoxic (Supplementary Figure S7), allowing us to perform
micromanipulation. Once mitotic entry occurred, we removed the zygotic chromosomes
(Fig.2d), and introduced interphase somatic donor nuclei (Fig.2e). Skin cells of an adult
healthy subject, or an adult type 1 diabetic subject served as nuclear donors.
Because nuclear remodeling correlates with reprogramming in the rhesus monkey29, we
monitored the transferred somatic chromatin hourly. We checked 46 of the 53 human
zygotes (53/69, 77%) that survived these manipulations and found that 43 had undergone
nuclear envelope breakdown and chromosome condensation within 6 hours after transfer
Egli et al. Page 3
Nat Commun. Author manuscript; available in PMC 2012 April 24.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t(Fig.2f, Supplementary Figure S8). Therefore, we concluded that early nuclear remodeling
was generally successful. As intended, the unreplicated donor chromosomes could not
satisfy the spindle checkpoint and therefore these zygotes remained in mitosis
(Supplementary Figure S9). To induce mitotic exit, while inhibiting abnormal cytokinesis,
we incubated zygotes in the cyclin-dependent protein kinase inhibitor purvalanol A, and the
kinase inhibitor, 6-DMAP. Importantly, nocodazole, purvalanol A, and 6-DMAP are
compatible with preimplantation development after nuclear transfer in mammalian species
including the rhesus monkey30-33, suggesting that little if any toxicity would be expected
when they are used. Within 4 hours of drug treatment, 53/53 zygotes exited mitosis and
entered the subsequent interphase (Fig.2g). Zygotes were then monitored for entry into the
subsequent mitosis, and within 30 hours, 33/53 (62%) completed the second cell-cycle.
Upon mitotic entry, 33/33 assembled a spindle (Fig. 2h,i), proceeded through chromosome
segregation, subsequent rounds of cleavage division (Fig. 2j,k), and two initiated
compaction (Fig.2l). However, we never observed further development to the blastocyst
stage (n=0/33).
Genome activation fails after transfer into human zygotes
Because we observed that all cleaving nuclear transfer cells generated using normal human
zygotes (33/33) arrested at a similar developmental stage (Fig. 3a), we wondered whether
there was a fundamental blockade to their development. Due to two observations we
considered the hypothesis that a failure to activate transcription was inhibiting development
after nuclear transfer. Our first observation was that green fluorescence from the H2B-GFP
protein transferred with the transgenic donor chromosomes was detectable at the first
interphase. However, fluorescence intensity decreased with every cleavage and never
returned (33/33 nuclear transfer specimen observed) (Fig. 3b). This observation suggested
that even the H2B-GFP coding sequence under control of the strong CAAGS promoter was
never again transcribed. In contrast, a similar transgene was routinely activated after mouse
nuclear transfer31 (Fig.3c). Second, we found that development after nuclear transfer
arrested at or shortly after the stage when major transcriptional activation in the embryo
normally occurs34,35. The steep increase in transcriptional activity in the normal embryo on
day3 after fertilization, or after the 4-cell stage, was also termed zygotic genome activation
(ZGA).
We next asked whether there was a more global deficit in transcription following human
nuclear transfer. To this end, we isolated RNAs from nuclear transfer and control embryos at
equivalent developmental stages (Supplementary Figure S10a) then analyzed their
transcriptional profiles using microarrays. To understand the normal changes in transcription
that occur during early stages of human cleavage development, we compared the profiles of
unmanipulated 1-cell zygotes collected on day 1 post IVF, to blastomeres of 6 to 8-cell
embryos collected on day 3 (approx. 72-84h post IVF) and day 4 of development (approx.
90-100h post IVF). Relative to the maternal RNAs present in fertilized zygotes (n=2
embryos), we found that 828 transcripts were significantly elevated (> 5-fold, p<0.01, see
Methods for statistical analysis) in all IVF samples (n=19 embryos, 4 biological replicates).
This result suggests there is substantial transcriptional activity already occurring at the 6 to
8-cell stage, as has previously been reported 35. In stark contrast, when the profiles of
developmentally advanced nuclear transfer samples were examined (n=2, 2 independent
biological replicates, 6-8 cell stage), only 101 (12%) of these 828 transcripts were increased
in their abundance relative to the 1-cell zygote (Fig. 3d) (>5-fold, p<0.01 for both samples).
As a control to ensure that we could accurately monitor transcriptional changes in nuclear
transfer blastomeres, we also monitored the decay of transcripts. At the cleavage stage, we
observed that 1130 maternal transcripts were subject to decay in all four control samples
collected on day 3 and day 4 after IVF. The levels of each of these transcripts declined by a
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tfactor of 5 or more during normal development from the 1-cell stage to the 6 to 8-cell stage
(<0.2-fold, p<0.01). Consistent with normal decay of a substantial fraction, but not all
maternal RNAs, we found that 493 (44%) of these transcripts were also reduced at the
cleavage stage following nuclear transfer (<0.2-fold, p<0.01) (Fig.3e).
To examine whether a somatic rather than an embryonic gene expression program was
active after nuclear transfer, we defined a set of 2153 transcripts that are transcribed at
higher levels in the somatic donor cells than in human zygotes (>10-fold, p<0.001 for two
somatic cell lines). Of the 2153 transcripts, 85 (4%) were elevated in nuclear transfer
samples (>5-fold higher levels than in zygotes, p<0.01 for 2 samples), while 350 (16%)
were elevated in control IVF embryos (>5-fold higher levels than in zygotes, p<0.01 for 4
samples). Expression of these 350 transcripts after nuclear transfer would not require
reprogramming, as they are already active in the somatic donor cell. Nevertheless, only 50
of them (14%) were elevated after nuclear transfer. This indicates that neither an embryonic
nor a somatic transcriptional program was being expressed, and even genes that do not
require reprogramming failed to be normally expressed after nuclear transfer.
Inhibition of transcription induces cleavage stage arrest
Our transcriptional analyses demonstrated that there was an unexpected failure to activate
transcription at the appropriate time following human nuclear transfer. These results raise
the possibility that development might arrest when the RNAs provided by the maternal
stores are no longer sufficient to promote development. If this hypothesis is correct, then
culture of normal fertilized zygotes in the transcriptional inhibitor alpha-amanitin should be
sufficient to induce a developmental arrest identical to that observed following nuclear
transfer. To test this idea, we cultured 23 zygotes for 5 days in the presence of the
transcriptional inhibitor alpha-amanitin (Fig.3a). We observed that 22/23 of these zygotes
cleaved and 10/23 developed to the 6 to 8-cell stage (Supplementary Table S1). However no
further development to the blastocyst stage occurred. In these arrested blastomeres, the
number of transcripts with elevated levels was very similar to nuclear transfer samples: only
46 of the 828 transcripts (5.5%, p<0.01) normally rising in abundance over the first three
days of development were increased >5 fold over the same time frame in alpha-amanitin
treated samples (n=2 specimen, 2 biological replicates)(Fig.3d). This result also suggests
that as many of the 101 ZGA transcripts elevated in nuclear transfer blastomeres may be
attributed to differential mRNA stability rather than active transcription. As observed after
nuclear transfer, treatment with alpha-amanitin did not completely interfere with the
degradation of maternal RNAs. We found that 590 of 1130 (47%, <0.2-fold, p<0.01)
transcripts that normally declined during cleavage also fell after alpha-amanitin treatment
(samples collected on days 3 and 4 after IVF) (Fig.3e). Therefore, pharmacological
inhibition of transcription was sufficient to induce changes in mRNA levels and a
developmental arrest identical to that observed after human nuclear transfer.
Reprogramming within hours after transfer into mouse zygotes
Although our experiments thus far suggest that there is a blockade to reprogramming using
human zygotes that is not present when mouse zygotes are used, our human nuclear transfer
protocol was technically distinct from the approach we had previously used for nuclear
transfer using mouse zygotes27. To rule out the possibility that technical aspects of our
human nuclear transfer procedure were preventing reprogramming, we used methods that
we developed here for human nuclear transfer and asked whether it could support efficient
development and reprogramming following nuclear transfer in mouse zygotes. To monitor
the state of reprogramming, we used tail tip fibroblasts carrying an Oct4-GFP transgene 36.
In striking contrast to our human experiments, we observed efficient development to the
morula and the blastocyst stages (significance of difference mouse-human: χ2=0.002, Chi-
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tsquare test) (Fig. 4a, Supplementary Table S3). We also found that within less than 36h,
GFP became activated from the somatic chromosomes, suggesting that reprogramming of
the Oct4 promoter had occurred and transcription initiated (Fig. 4a). This reprogramming
following nuclear transfer was far more rapid than observed following induction of
pluripotency in mouse fibroblasts using defined transcription factors37,38 (Fig. 4b). We also
controlled for the effects of cryopreservation by performing nuclear transfer into frozen-
thawed mouse zygotes. These zygotes gave rise to blastocysts after nuclear transfer
(Supplementary Table S2). Thus, we can conclude that even when precisely the same
nuclear transfer methods are used, mouse zygotes supported reprogramming, while human
zygotes could not.
To more broadly determine whether transcriptional initiation was occurring normally after
mouse nuclear transfer into zygotes, we performed transcriptional profiling. In contrast to
the situation in human development, where ZGA occurs at the 4-8 cell stage35, in mouse,
ZGA occurs at the 2-cell stage39. Surprisingly, we found that transcriptional reprogramming
was essentially complete by the end of first the cell cycle, or 22-24 hours after nuclear
transfer. 934/1025 (91%) of transcripts that were upregulated between control mouse
zygotes and the 2-cell stage, were also upregulated after nuclear transfer (>5x, P<0.01) (Fig.
4c). Chemically mock-treated control zygotes upregulated a similar number of transcripts
(898/1025, 88%). Remarkably, of 179 transcripts that were upregulated at the 2-cell stage
relative to the zygote (>5-fold, P<0.01) and that were not expressed in tail tip fibroblasts,
151 were also upregulated after nuclear transfer, and 154 in mock-treated controls. This
level of reprogramming was identical to that observed after nuclear transfer into mouse
oocytes; the transcriptome of nuclear transfer embryos generated with zygotes clustered
closely with unmanipulated 2-cell embryos, and nuclear transfer embryos generated with
oocytes clustered closely with parthenotes (Fig. 4d).
To better understand the mechanism of reprogramming in mouse zygotes, we transferred
somatic cells at various time points of mitosis. When somatic nuclei were transferred at
prometaphase, chromosome condensation occurred within 2 hours post transfer (Fig. 5a,b).
In contrast, when nuclei were transferred at anaphase of mitosis, chromosome condensation
did not occur and nuclear remodeling required 20 or more hours (Fig. 5c-e). Reprogramming
and development after nuclear transfer into mouse zygotes was strictly dependent on nuclear
remodeling by chromosome condensation. The transcriptome of zygotes transferred at
anaphase clustered most closely with genome-less embryos, (Fig. 5f). Only 212/1025
(20.7%) ZGA genes were normally expressed after nuclear transfer at anaphase (Fig. 5g),
and of 179 ZGA genes silent in the somatic donor cell, only 23 (12.8%) were normally
upregulated (Supplementary Figure S11a). Furthermore, all embryos arrested at the 2-cell
stage when interphase nuclei were transferred (Fig. 5h, Supplementary Table S3). This
observation raised the question whether a failure to condense somatic chromatin could be
responsible for the transcriptional and developmental phenotype after nuclear transfer into
human zygotes. However, this was not the case, as we found that 40/46 human zygotes
underwent nuclear envelope breakdown and chromosome condensation within 3 hours after
transfer (Supplementary Figure S8).
Abnormal karyotypes do not cause transcriptional failure
It has been suggested that mitotic abnormalities after primate nuclear transfer 40 cause
karyotypic aberrations that contribute to developmental arrest. We therefore used
fluorescence in situ hybridization to investigate whether similar abnormalities occurred after
human nuclear transfer and whether they might induce the transcriptional failures we
observed. Although some chromosome abnormalities were observed, (Supplementary Figure
S12), abnormalities were also found in IVF blastomeres (Supplementary Table S4), many of
which continue development to the morula and blastocyst stage.
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failures, we intentionally induced aneuploidy in otherwise normal fertilized controls, then
monitored their transcriptional activity. To induce karyotypic abnormalities, we suppressed
the first cleavage division, thus generating tetraploid cells with supernumerary centrosomes
(Fig. 6a). These cells formed multipolar spindles at the next mitosis and directly cleaved into
either 3 or 4 cells instead of 2 (Fig.6b, Supplementary Table S5). As a consequence of the
asymmetric segregation of chromosomes, the resulting blastomeres would be expected to
have abnormal karyotypes. Despite their presumably abnormal karyotypes, we found that
these blastomeres (n=2, 1 replicate) initiated transcription (489/828 ZGA genes or 59% were
upregulated at least 5 fold, p<0.001) (Supplementary Figure S13), and therefore their
transcriptional profiles clustered closely together with normal IVF samples, and not with the
nuclear transfer samples (Fig.6c). Therefore, karyotypic abnormalities are not sufficient to
explain the transcriptional failures we have observed following human nuclear transfer.
Furthermore, as these zygotes were treated with nocodazole and the kinase inhibitors 6-
DMAP and purvalanol A to inhibit cytokinesis, the same drugs as in our nuclear transfer
protocols, they control for the effect of these drugs on transcriptional activation of the
genome. We found that the transcriptional profile of these drug treated control zygotes
clustered with untreated control embryos and clustered separately from nuclear transfer
embryos (Fig. 6c). Therefore, the drugs used are not directly responsible for the
transcriptional failures observed after somatic cell nuclear transfer.
Nuclear transfer into zygotes with supernumerary pronuclei
Human zygotes fertilized by more than one sperm41, or which do not complete meiosis
normally, are routinely discarded because of their abnormal chromosome content. We have
shown that mouse polyspermic zygotes can serve as competent recipient cells27 and
therefore attempted to use 29 analogous human zygotes for nuclear transfer.
As has been observed previously42,43, when the development of 7 of these zygotes was
monitored, they underwent abnormal cytokinesis (Supplementary Table S5). We found that
the unusual cleavage pattern that resulted was caused by the nucleation of tripolar or
tetrapolar mitotic spindles with supernumerary centrosomes at the spindle poles (Fig. 7a).
We hoped that by arresting these zygotes in mitosis (Fig. 7b) and then removing their
abnormal spindles, we might replace them with donor nuclei that would support normal
cytokinesis. After we transferred nuclei into these mitotic zygotes, we again observed
nuclear envelope breakdown and chromosome condensation (Fig. 7c). Following mitotic
exit and inhibition of cytokinesis, entry into the second interphase occurred normally.
However, in all instances, the next cleavage division was multipolar (Supplementary Table
S5), resulting in more than two, presumably aneuploid daughter cells and developmental
arrest on day3 after fertilization (Fig.7d). Our results suggest that we were unable to remove
supernumerary centrosomes during enucleation. Multipolar cleavage in human tetraploid
zygotes was in striking contrast to both mouse and rabbit zygotes. In those species,
tetraploid or polyspermic zygotes made a normal cleavage division, and efficiently
developed to the blastocyst stage (Supplementary Table S6). These results suggest that the
centrosome has a more dominant role in directing spindle assembly and cytokinesis in
human development than it does in other species. This observation has substantial
ramifications for human nuclear transfer and suggests that if more than one centrosome is
present in the zygote after manipulations are completed, then abnormal patterns of spindle
assembly and cleavage will occur.
Egli et al. Page 7
Nat Commun. Author manuscript; available in PMC 2012 April 24.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tDiscussion
Here, we report our attempts to overcome the logistical and scientific obstacles impeding the
production of patient-specific stem cell lines by nuclear transfer. While it has been difficult
to recruit “altruistic” oocyte donors24 we did succeed in sourcing more than 400 normally
fertilized eggs (zygotes) for our nuclear transfer studies.
Development after nuclear transfer was normal through the cleavage stages, but, unlike IVF
controls, all cleaving nuclear transfer cells arrested before or at the time of compaction with
severe transcriptional abnormalities. An identical phenotype could be induced by inhibition
of transcription in IVF controls, but not by the deliberate induction of karyotypic
abnormalities, suggesting that transcriptional defects are more proximally responsible for the
developmental arrest.
Our findings are not the trivial result of a small sample size. Instead our results of more than
160 nuclear transfer experiments and more than 200 control manipulations indicate that
there is a robust species-specific blockade to reprogramming that must be overcome before
human stem cell lines can be derived. Our work and those of others suggests that the
developmental arrest we observed is not simply the result of using zygotes for nuclear
transfer as a temporally similar arrest is commonly observed after nuclear transfer into to
human unfertilized oocytes18,20,25. Although a single group has reported efficient
transcriptional reprogramming after human nuclear transfer20, they compared somatic cells
to nuclear transfer samples and their results are therefore confounded by the presence of
maternal mRNAs, which were not appropriately accounted for by their analyses. Another
group has generated a single blastocyst after transfer of embryonic stem cell nuclei into
human oocytes17, but development arrested when fibroblasts were transferred using
identical methods18. This suggests that development and activation of the transferred
genome depend on the epigenetic state of the injected nucleus.
In contrast to human zygotes, when we performed nuclear transfer into mouse zygotes, we
found that reprogramming was essentially complete within hours and indeed within a single
cell cycle. This result also points to a fundamental difference between reprogramming after
nuclear transfer and iPS reprogramming: at least in animals, nuclear transfer mediates an
immediate transition from a somatic to a pluripotent gene expression pattern, while
reprogramming by defined factors seems to be a gradual process, requiring days or
weeks37,38. It is interesting to consider that this could explain why stem cells generated by
nuclear transfer are indistinguishable44 from stem cells derived from fertilized blastocysts,
while in mouse16,45 and human12,15,46-48 iPS cell reprogramming may at times be less
complete.
Incomplete reprogramming and developmental defects after somatic cell nuclear transfer
have been described in other vertebrate species36,49-54. For example, in bovine nuclear
transfer embryos, 3.8% of genes were found to be incompletely reprogrammed53. This is
comparable to the results reported here with mouse zygotes, where the majority of
transcripts (>91%) are normally expressed within 24 hours after nuclear transfer. In contrast,
the transcriptional defects after nuclear transfer into human zygotes, extend far beyond
incomplete reprogramming of a few genes: the majority of transcripts, or more than 88%,
were not normally expressed. Surprisingly, even genes that were active in the somatic donor
cell were not normally expressed, suggesting a failure to properly activate the transferred
somatic cell genome.
The species-specific differences in transcription after nuclear transfer might be due to a
property of the human egg, or of the human somatic cells. Our results suggest that
investigating the requirements for transcriptional activation of the donor cell genome may
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thelp to overcome the developmental arrest commonly observed after human nuclear
transfer.
Methods
Human zygotes were obtained using protocols reviewed and approved by the Committee on
the Use of Human Subjects (IRB) and the Stem Cell Research Oversight Committee
(ESCRO) at Harvard University.
Nuclear transfer into human zygotes
Human zygotes were thawed with Quinn's Advantage Thaw Kit (Cooper Surgical). Zygotes
were thawed in small groups, from 6-12 for a single experiment. Upon thaw, zygotes were
washed and placed in microdrops of Global media under mineral oil, equilibrated over night
at 37 deg., 5% CO2. The 307 zygotes surviving the thaw were used as follows: 151 for
nuclear transfer experiments, 77 for other experimental manipulations, 12 for
immunohistochemistry and RNA analysis, 28 as developmental controls, and the remainder
for developmental controls and the characterization of zygotic mitosis.
The following nuclear transfer protocol emerged as the most practical: nocodazole was
added 1-2 hours post thaw at a concentration of 50μg/ml. Lower nocodazole (Sigma)
concentrations (0.1 μg/ml) were ineffective for human zygotes (Supplementary Figure S13,
Supplementary Table S7, Supplementary Figure S14). Without addition of nocodazole prior
to spindle removal, most spindle material was removed with the zygotic genome
(Supplementary Fig.S15), resulting in developmental arrest and the formation of abnormal
spindles at the next mitosis (Supplementary Table S1). Upon entry into mitosis, zygotes
were stained with Hoechst 33342 (2μg/ml) (Sigma) for 5-10 minutes in GMOPS-plus
containing nocodazole. Zygotes were then placed on the heated stage in microdrops
containing 10μg/ml CytoB and 50μg/ml nocodazole to generate a fluid cytoplasm. A hole
was made in the zona pellucida with a XYClone Laser (Hamilton Thorne) using two to four
500-600μs pulses. The DNA was removed using a fire-polished pipette to prevent lysis
(73/116 zygotes, 63%, survived the enucleation step). Chromosomes were visualized by low
intensity UV illumination and/or Hoffman Modulation Contrast Optics. Removal of
genomic DNA was verified by the presence of Hoechst/DNA complex in the removed
material and the absence in the zygote. A second hole was made and a somatic cell inserted
below the zona pellucida. Somatic cells were allowed to reach confluency to induce cell
cycle arrest (for both human or mouse somatic cells, this usually occurred within a week
after passage), and maintained as confluent cultures until use for nuclear transfer (between
one week to two months after reaching confluency). In some instances, cells were exposed
to medium containing 0.5% serum for 1 day before use for nuclear transfer. Fibroblasts
obtained from a male adult T1D subject (ID#1011) or an adult healthy male (ID#1003) with
a normal karyotype (Supplementary Figure S16) were used as nuclear donors. . Fusion of
the somatic cell was done using two DC pulses of 1.6kV/cm of 20ms width using LF101
(NEPA GENE) in cell fusion medium 0.26M mannitol, 0.1mM MgSO4, 0.05% BSA,
0.5mM HEPES. 94 of 95 zygotes (99%) fused under these conditions, and none of them
lysed. Using Piezo-mediated injection only 7/24, or 29% recovered from the lesion. Upon
fusion, zygotes were returned to the incubator in Global culture medium. Chromosome
condensation was monitored at least every hour using GFP fluorescence. After 2-3 hours
chromosome condensation had occurred and zygotes were stimulated to exit mitosis without
cleavage using 2.5mM 6-DMAP and 25μM purvalanolA (Sigma P4484), in Global medium.
After 4-5 hours, when interphase nuclei were apparent, zygotes were thoroughly washed and
then cultured in Global medium supplemented with 15% plasmanate.
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concentration of 50μg/ml. Our total survival rate for the total of 160 nuclear transfer
manipulations was 108/160 or 67%.
Microarray analysis
For microarray analysis, total RNA was isolated using PicoPure RNA isolation kit
(Molecular Devices), and RNA was amplified by two to three rounds of T7 transcription
using the Illumina TotalPrep RNA Amplification Kit. Amplified RNA was hybridized to the
to Illumina® Sentrix Human Gene Expression BeadChip® RefSeq 8 v3.0 and read by the
Illumina Bead Array Reader. Analysis was done using the Illumina Genome Studio Program
and Microsoft Excel. Data was normalized to average and a differential gene expression
score calculated in comparison to 1-cell zygotes as reference. Fold change to 1-cell zygotes
were calculated based on the average signal for a particular transcript using Microsoft Excel.
The average fold change for two samples was calculated (e.g. two samples on d3 post IVF, 2
samples on d4 post IVF, 2 samples treated with amanitin, 2 NT samples, etc). If the average
fold change was >5 or <0.2, and the differential gene expression score was >22 or <-22,
corresponding to a p-value of <0.01 for both samples, a transcript was considered
differentially expressed. Differential gene expression score (DIffscore) is calculated by the
Illumina Genome Studio program using an Illumina custom algorithm. A diffscore of >33 or
<-33 corresponds to a P-value of <0.001. All p-values indicated in the manuscript were
calculated in this manner. The 828 ZGA transcripts and the 1130 maternal mRNA decay
transcripts were at least 5x differentially expressed in the set of both d3 and d4 IVF data
points, each consisting of two samples.
Nuclear transfer into mouse zygotes and oocytes
Nuclear transfer protocols developed on human zygotes were used for nuclear transfer into
mouse zygotes. In brief, tail tip fibroblasts used for nuclear transfer and iPS generation were
obtained from adult B6jcBA-Tg (Pou5fI-EGFP)2Mnn/J mice. Mouse somatic cells were
prepared for nuclear transfer as described above for human somatic cells. Zygotes and
oocytes were obtained from BDF1 mice (Charles River). Zygotes were arrested in mitosis
by nocodazole and had their genome removed shortly (5-10min.) after release from
nocodazole with or without the use of Hoechst/low intensity UV illumination. Nuclear
transfer was done by two DC pulses of 1.6 kV/cm in fusion buffer (71/98 or 72% of tail tip
cells fused and integrated into the recipient zygote). Cytokinesis was inhibited by incubation
inhibited by the same combination of kinase inhibitors as used for nuclear transfer in human
zygotes: 10μM of the cyclin-dependent kinase inhibitor purvalanol A (Sigma P4484), 2mM
6-DMAP (Sigma D2629), 0.5μg/ml nocodazole, and optionally with the addition of 20μM
of the aurora B kinase inhibitor ZM 447439 (Tocris Bioscience) for 90-120 minutes. For
nuclear transfer at anaphase, zygotes had their genome removed at anaphase (40-50min post
nocodazole release) or, alternatively, the genome was removed at prometaphase and zygotes
were stimulated to enter anaphase as above (cytokinesis inhibitors purvalanol A, 6-DMAP
and nocodazole) for 45-60 minutes prior to transfer. Control zygotes that had cytokinesis
inhibited with these same cytokinesis kinase inhibitors efficiently developed to the morula
and blastocyst stage (9 blastocysts and 1 morula of 10 zygotes), suggesting that the
combination of these drugs is not toxic to mouse preimplantation development. Nuclear
transfer into mouse oocytes was done as follows: oocytes were obtained 14 h post hCG
injection, their spindle-chromosome complex was removed in the presence of 5μg/ml
cytochalasinB. Tail tip fibroblasts were transferred into enucleated oocytes by direct
injection, and activated by 5 hours incubation in 1mM SrCl2 in ca-free MZCB and 5μg/ml
cytochalasinB to inhibit polar body extrusion, as described elsewhere 55,56. Array data on
nuclear transfer into interphase zygotes and on genome less zygotes were obtained from
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tRef. 31. Drug treatment only controls were arrested as zygotes with nocodazole, and
cytokinesis was inhibited with the use of purvalanol A and 6-DMAP.
For gene expression analysis, RNA was isolated from groups of approx. 20 cells, amplified
by 2 rounds of T7 polymerase transcription and hybridized to Illumina arrays. Differentially
expressed genes were defined as having a Diffscore of > 22 or < than -22 in two samples of
the same kind, and an at least 5-fold difference in the average signal (average of both
samples). Interphase zygotes were harvested 25-28h post hCG pulse, mitotic zygotes were
obtained by nocodazole mediated arrest until 33h post hCG.
iPS generation
Plat-E packaging cells were transfected (Fugene, Roche) with retroviral plasmids for Oct4,
Sox2, Klf4 or c-Myc and viral supernatent was collected, filtered, combined to contain virus
of all four transcription factors, and placed on tail tip cells obtained from adult B6jcBA-Tg
(Pou5fI-EGFP)2Mnn/J mice. In brief,cells on 3 consecutive days, as previously described
(Ichida et al. 2009). The first application of viral supernatant was counted as day 0.
Immunostaining
Zygotes, blastomeres and blastocysts were fixed in 4% paraformaldehyde over night at 4°C,
permeabilized in PBS with 0.5% Triton-X100 (PBS/T) for 20min., blocked in blocking
solution consisting of 0.1% PBS/T with 10% FBS over night at 4°C, incubated in primary
antibody at 4°C in blocking solution, then washed for 1h at room temperature in 0.1% PBS/
T, incubated with secondary conjugated antibody in 0.1% PBS/T at room temperature for
1h, washed as above, stained with Hoechst 33342 for 5 minutes and used for confocal
imaging. Oct4 antibody (Santa Cruz, sc5279) and Cdx-2 antibody (Biogenex) was used at a
concentration of 1:200, and Brg-1 antibody (Santa Cruz sc-10768) was used at a
concentration of 1:50. Conditions were maintained between different samples. BrdU
labeling was done using the Amersham cell proliferation kit (RPN20). Cells were incubated
into the labeling solution diluted 1:1000 in KSOM for 18h post transfer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Donation of human zygotes for stem cell research
a, embryos donated for stem cell research. PN= pronucleus, ND= not determined b, Mitotic
entry time of human zygotes (n=107) in hours after thaw. Nuclear envelope breakdown of at
least one of the two pronuclei was defined as the time point of mitotic entry. Some zygotes
were mitotic at the time of thaw. c, mitotic spindle formation. Human zygote 30 minutes
after nuclear envelope breakdown including brightfield image, microtubule
immunohistochemistry (arrowheads point to the centrosome at both poles of the spindle) and
spindle birefringence. d-f, asynchrony in nuclear envelope breakdown. d, Hours between the
breakdown of the first pronuclear envelope and the second. e, Zygote with asynchronous
pronuclear envelope breakdown. Numbers indicate the time from the breakdown of the first
nuclear envelope. The location of mitotic chromatin is circled. f, 1PN zygote stained for
phosphorylation of Ser 27 on Histone H3, a marker of mitosis.
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tFigure 2. Somatic cell nuclear transfer into human zygotes
a, Schematic of nuclear transfer into human zygotes. b, zygote at 2PN stage in the presence
of nocodazole. Size bar applies to all panels except where otherwise indicated. c, zygote at
mitosis in the presence of nocodazole. Maternal and paternal haploid genomes are circled. d,
paternal and maternal haploid genomes removed from the zygote. e, Somatic cell nuclear
transfer (green nucleus marked by H2B:GFP) by fusion, f, chromosome condensation, g,
and after exit from mitosis. Time post exit from mitosis is indicated. h,spindle assembly i,
chromosomes aligned at metaphase. j, cleavage, k, 6-cell stage, l, morula-like, on d4 post
fertilization. Size bar: 25μm.
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tFigure 3. Developmental potential and ZGA after nuclear transfer into human zygotes
a, Developmental potential of control IVF human zygotes (black columns, n=28), zygotes
after nuclear transfer (blue columns, n=53), and zygotes cultured in the presence of alpha-
amanitin (red columns, n=23) displayed as the percentage of cells developing to and beyond
the indicated developmental stage. b, GFP expression after human nuclear transfer. c,
Transgene reactivation after mouse nuclear transfer. Shown are nuclear transfer cells 2 days
after transfer into mouse zygotes. d, Genome activation after human SCNT. Venn diagrams
of genes upregulated >5-fold in the indicated groups, e, maternal mRNA degradation after
human SCNT. Venn diagram of genes with transcript levels reduced by a factor of 5 or more
in the indicated groups. NT=nuclear transfer, ZGA=zygotic genome activation. Size bar:
25μm.
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tFigure 4. Transcriptional reprogramming within hours after mouse nuclear transfer
a, Oct4::GFP reprogramming after somatic cell nuclear transfer into mouse zygotes. b,
Number of Oct4-GFP+ colonies during mouse iPS generation. Kinetics of Oct4::GFP
reactivation in somatic cells after transduction with retroviruses carrying the reprogramming
factors Oct4, Sox2, Klf4 and c-Myc. Day 8 is the 8th day after the first exposure of somatic
cells to viral vectors. c,d, ZGA and reprogramming 22h after nuclear transfer into mouse
zygotes. c, Venn diagram of transcripts elevated at the 2-cell stage. d, cluster diagram of the
global gene expression profile after nuclear transfer into oocytes or zygotes. * from ref. 31.
Size bar 10μm.
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tFigure 5. Chromosome condensation is required for development and reprogramming after
nuclear transfer into mouse zygotes
a, schematic for nuclear transfer into prometaphase and b, corresponding images. Nuclei of
fibroblasts at interphase are transferred into a zygote at prometaphase of mitosis.
Chromosomes are marked with the red fluorescent fusion protein H2B-cherry. Shown is the
mitotic progression after nuclear transfer. Time indicates the hours after nuclear transfer.
Note the condensation of chromosomes and their separation into two groups, followed by
formation of 2 pronuclei after inhibition of cytokinesis and entry into interphase. c, removal
of the genome from a zygote at anaphase. d, Nuclear morphology after transfer of interphase
nuclei. Small inset: a somatic donor cell before transfer. Note that somatic donor chromatin
is not condensed. e, nuclear remodeling is slow and requires about 1 day to restructure the
nucleus into a large blastomere-like morphology. f, cluster analysis of gene expression after
mouse SCNT. g, Venn diagram of transcripts elevated 22-24h after nuclear transfer at
anaphase. h, development to morula and blastocyst stage (as % of transferred). Size bar
10μm.
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tFigure 6. Failure to initiate transcription is not caused by karyotypic abnormalities
a, Induction of aneuploidy in human zygotes. Schematic showing development after
suppression of cleavage at the first mitosis. b, Development after suppression of cleavage at
the first mitosis. Arrows point to a multipolar spindle as detected by microtubule
birefringence. Immunohistochemistry at anaphase of mitosis shows the asymmetric
segregation of chromatin to three poles (outer surface of the cleaving cell is outlined). Final
panel: cleavage directly to 4 cells. NT=nuclear transfer. Days indicated the time post IVF. c,
Clustering of the transcriptome of the indicated samples. Size bar 25μm.
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tFigure 7. Nuclear transfer into human polyspermic zygotes
a, Immunocytochemistry of dispermic human zygotes at mitosis. Arrowheads point to
pericentrin positive centrosomes, arrows to tubulin positive sperm tails. b, Entry of
polyspermic zygotes into mitosis. c, Nuclear transfer into human polyspermic zygotes.
Genome removed at mitosis, fusion with a somatic donor cell and chromosome
condensation of the somatic cell genome 2h post transfer are shown. d, Cleavage and
development after nuclear transfer into polyspermic zygotes. Time indicates the days post
fertilization. The arrow points to a birefringent spindle.
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